Exscientia Yönetim

Yönetim kriter kontrolleri 1/4

Exscientia CEO'su Dave Hallett, Feb2023 tarihinde atandı, in görev süresi 1.75 yıldır. şirketin hisselerinin 0.001% doğrudan sahiptir ve bu hisselerin değeri $ 7.29K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 3.8 yıldır.

Anahtar bilgiler

Dave Hallett

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.8yrs
CEO sahipliği	0.001%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)

Feb 26

Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?

Jan 11

Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 12

New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)

Aug 31

We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Aug 25

Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher

Jul 21

Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans

Apr 22

We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Dec 30

The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts

Aug 31

Exscientia: Using AI To Power Drug Development

Aug 15

Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth

May 29

CEO

Dave Hallett (55 yo)

1.8yrs

Görev süresi

Dr. David Hallett, also known as Dave, Ph.D. is the Chief Operations Officer of Exscientia Limited since January 2020. He served as Chief Operating Officer at Exscientia plc since June 2022 until 2022 and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Hallett	Chief Scientific Officer	1.8yrs	Veri yok	0.0011% $ 7.3k
John Overington	Chief Technology Officer	less than a year	Veri yok	0.015% $ 94.8k
Sara Sherman	Vice President of Investor Relations	no data	Veri yok	Veri yok
Dan Ireland	Executive VP of Legal & Company Secretary	1.8yrs	Veri yok	Veri yok
Parker Moss	Executive Vice President of Corporate Development	less than a year	Veri yok	Veri yok
Caroline Rowland	Chief People Officer	2.2yrs	Veri yok	Veri yok
Richard Law	Chief Business Officer	no data	Veri yok	Veri yok
Nikolaus Krall	Executive Vice President of Precision Medicine	1.8yrs	Veri yok	Veri yok
Marie-Louise Fjallskog	Interim Chief Medical Officer & Clinical Development Lead	less than a year	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: EXAI 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Hallett	Chief Scientific Officer	less than a year	Veri yok	0.0011% $ 7.3k
Elizabeth Crain	Independent Non-Executive Chairman	3.8yrs	UK£282.03k	0.088% $ 557.4k
Mario Polywka	Independent Non-Executive Director	7.2yrs	UK£201.69k	0.052% $ 330.3k
Robert Ghenchev	Independent Non-Executive Director	4.5yrs	Veri yok	Veri yok
Franziska Michor	Independent Director	1.5yrs	UK£178.86k	0.028% $ 175.7k

3.8yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: EXAI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Exscientia Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

Exscientia plc, Annual General Meeting, May 15, 2024

Chief Scientific Officer notifies of intention to sell stock

Parker Moss to Join Exscientia as EVP, Corporate Development

Recent updates

New major risk - Revenue and earnings growth

Exscientia plc(NasdaqGS:EXAI) dropped from NASDAQ Biotechnology Index

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates decrease by 14%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 60%

Exscientia plc Reports Impairment for the Second Quarter Ended June 30, 2024

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for approximately $640 million.

Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for

Chief Scientific Officer notifies of intention to sell stock

Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation

New major risk - Revenue and earnings growth

The Schall Law Firm Announces Class Action Lawsuit Against Exscientia plc

Exscientia: Too Much Pessimism

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.38 loss in 1Q 2023)

Exscientia: Drug Discovery Platform Attracting Partners And Cash

Exscientia plc to Report Q1, 2024 Results on May 21, 2024

Holzer & Holzer, LLC Files Class Action Lawsuit on Behalf of Exscientia P.L.C. Investors

Exscientia plc, Annual General Meeting, May 15, 2024

Consensus EPS estimates fall by 22%

New minor risk - Shareholder dilution

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Exscientia plc to Report Fiscal Year 2023 Results on Mar 21, 2024

Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)

Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?

Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates increase by 23%

Consensus revenue estimates decrease by 12%, EPS upgraded

New minor risk - Shareholder dilution

Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Exscientia plc to Report Q3, 2023 Results on Nov 09, 2023

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc to Present New Preclinical Data for AI- Designed LSD1 and MALT1 Inhibitors at ESMO 2023

New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)

Consensus revenue estimates increase by 23%

We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Consensus revenue estimates decrease by 25%, EPS upgraded

New major risk - Share price stability

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Exscientia plc to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates increase by 18%

Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher

Exscientia plc Initiates Prospective Observational Study in Ovarian Cancer

Exscientia plc Announces First Patient Enrolled in Phase 1/2 ELUCIDATE Trial Assessing GTAEXS617 in Advanced Solid Tumours

First quarter 2023 earnings released: US$0.38 loss per share (vs US$0.17 loss in 1Q 2022)

Exscientia plc Highlights "The Future of AI-Enabled Drug Discovery" at SLAS Europe

Exscientia plc to Report Q1, 2023 Results on May 24, 2023

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Consensus EPS estimates upgraded to UK£1.49 loss, revenue downgraded

Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates increase by 29%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Exscientia plc Highlights New Data to Identify Patients That Are More Likely to Respond to Its A2a Receptor Antagonist, Exs-21546

Exscientia plc Receives First clinical trial application Approval to Initiate IGNITE-AI, Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours

Consensus forecasts updated

Third quarter 2022 earnings released

Exscientia plc to Report Q3, 2022 Results on Nov 15, 2022

Blood Cancer Discovery Publication Further Validates Exscientia's Ai Precision Medicine Platform for Improving Patient Outcomes

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts